DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qbqz8d/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - UK Drug Forecast and Market Analysis to 2022" report to their offering.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Our primary research reveals that UK hemophilia B patients have relatively lower rates of rFIX prophylaxis compared with other 5EU and US markets. This low rate of prophylaxis in hemophilia B patients will be a barrier to growth in the UK over the forecast period.
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Hemophilia A and B market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Major Brands, Hemophilia A
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant))
5.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free)
5.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.4 Product Profiles - Hemophilia B
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant])
5.4.2 Rixubis (BAX-326)
5.5 Product Profiles - Hemophilia A and B with Inhibitors
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant])
6 Opportunity and Unmet Need
6.2 Opportunities Analysis
6.3 Unmet Needs Gap Analysis
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development - Hemophilia A
7.2.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein)
7.2.2 BAY 94-9027 (octocog alfa)
7.2.4 Novoeight (turoctocog alfa; NN7008)
7.2.5 N8-GP (NN7088)
7.2.6 CSL-627 (rFVIII-SC)
7.3 Promising Drugs in Clinical Development - Hemophilia B
7.3.1 Alprolix (rFIXFc)
7.3.2 CSL-654 (rIX-FP)
7.3.3 N9-GP (NN-7999)
7.3.4 IB1001 (trenacog alfa)
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors
7.4.1 BAX-817 (rFVIIa BI)
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/qbqz8d/pharmapoint